Advertisement

Pharmacy World & Science

, Volume 32, Issue 2, pp 114–116 | Cite as

Dopamine agonist induced compulsive eating behaviour in a Parkinson’s disease patient

  • Waqas Khan
  • Abdul Qayyum RanaEmail author
Case Report

Abstract

Case description: a patient diagnosed with type 2 diabetes mellitus and Parkinson’s disease developed a compulsive eating disorder when treated with a dopamine agonist, pramipexole. The patient had no history of psychiatric illnesses and upon the discontinuation of pramipexole his abnormal behavioural symptoms were resolved. Conclusion: Physicians treating Parkinson’s disease patients with dopamine replacement therapy should inquire about the development of any compulsive behaviours. Although uncommon, many of these non-motor symptoms go undiagnosed and can have a detrimental impact on a patient’s quality of life.

Keywords

Compulsive eating Dopamine agonists Dopamine replacement therapy Impulse control disorders Parkinson’s disease Pramipexole 

Notes

Acknowledgements

Sughra Naz (Toronto, Ontario, Canada).

Conflict of Interest

None to declare.

References

  1. 1.
    Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease: incidence, neurobiological basis, management and prevention. Drug Saf. 2009;32(6):475–88.CrossRefPubMedGoogle Scholar
  2. 2.
    Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord. 2006;21(4):524–9.CrossRefPubMedGoogle Scholar
  3. 3.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association; 2000.Google Scholar
  4. 4.
    Miwa H, Kondo T. Alteration of eating behaviors in patients with Parkinson’s disease: possibly overlooked? Neurocase. 2008;14(6):480–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Voon V, Potenza MN, Thomsen T. Medication-related impulse control and repetitive behaviors in Parkinson’s disease. Curr Opin Neurol. 2007;20(4):484–92.CrossRefPubMedGoogle Scholar
  6. 6.
    Weintraub D. Dopamine and impulse control disorders in Parkinson’s disease. Ann Neurol. 2008;64(Suppl 2):S93–100.PubMedGoogle Scholar
  7. 7.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther. 2004;26(9):1427–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Weintraub D, Potenza MN. Impulse control disorders in Parkinson’s disease. Curr Neurol Neurosci Rep. 2006;6(4):302–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  1. 1.Department of Nutritional Sciences, Faculty of MedicineUniversity of TorontoTorontoCanada
  2. 2.Rouge Valley Hospital, Parkinson Clinic of Eastern Toronto and Movement Disorders CenterTorontoCanada

Personalised recommendations